account_balance Nasdaq: ANIX

Two differentiated cancer programs. Multiple 2026 catalysts.

Anixa Biosciences (Nasdaq: ANIX) is advancing an ovarian cancer CAR-T program targeting solid tumors and a breast cancer vaccine. As its pipeline advances across high-need oncology indications, the Company is positioned to unlock meaningful value through upcoming clinical milestones and long-term growth opportunities.

Anixa Biosciences company overview
Company overview
Fox News breast cancer vaccine coverage
Fox News coverage
Recent highlights

Clinical momentum and catalyst visibility

Recent survival observations in the ovarian cancer CAR-T program, completion of the Phase 1 breast cancer vaccine study, IND transfer, broader international patent progress and increased public visibility highlight the Company's rapid progress.

Ovarian cancer CAR-T program

Encouraging survival observations and protocol advancement in the ongoing Phase 1 trial.

Breast cancer vaccine

Phase 1 completed with favorable tolerability and protocol-defined immune responses.

Near-term focus

Clinical milestones, regulatory progress and broader international patent momentum.

pie_chart
33M Shares outstanding (Jan 31, 2026)
account_balance
$14M Cash and short-term investments. 2+ year runway
verified
No Debt No debt, no preferred stock, no warrants
science
Phase 1 Ovarian cancer CAR-T program active in clinic
rocket_launch
Phase 2 Setup Breast cancer vaccine moving toward next clinical stage

A biotech company trying to treat and prevent cancer with the immune system.

Anixa Biosciences is developing immunotherapies that teach the body to fight cancer on its own. Their ovarian cancer program uses a differentiated CAR-T cell therapy designed for solid tumors. Their breast cancer program is a vaccine that could prevent cancer before it starts. Both programs are developed in collaboration with leading research institutions.

vaccines

Cancer vaccine platform

Targets "retired" proteins that reappear in cancer cells. The breast cancer vaccine completed Phase 1 with favorable tolerability and immune responses, and is advancing toward Phase 2.

biotech

Solid tumor CAR-T

Lira-cel targets FSHR on ovarian tumors, one of the hardest problems in oncology. Currently in Phase 1 with encouraging survival observations.

partner_exchange

Partnered with world-class institutions

Partnerships with Cleveland Clinic, Moffitt Cancer Center, The Wistar Institute, Department of Defense, and National Cancer Institute.

shield

Prevention, not just treatment

The vaccine platform supports both therapeutic and prevention-oriented applications, which is one of the most differentiated elements in the Anixa story.

public

Growing patent portfolio

International patent allowances continue to expand IP protection across multiple jurisdictions and cancer types.

savings

Clean balance sheet

$14M in cash and short-term investments as of January 31, 2026. No debt, no preferred stock, no warrants.

Near-term catalysts (6-12 months)

Multiple clinical, regulatory, and strategic milestones are expected across both programs.

Clinical read-through

  • check_circle
    Ovarian cancer CAR-T program dose escalation

    Progress into higher-dose evaluation under the amended protocol.

  • check_circle
    Periodic data visibility

    Enrollment-based updates keep the program in view as cohorts advance.

Regulatory and development execution

  • check_circle
    Breast cancer vaccine Phase 2 path

    Program now positioned for next-stage clinical advancement.

  • check_circle
    Regulatory progression

    Operational control and protocol progression support upcoming development milestones.

External visibility

  • check_circle
    Potential partnerships or licensing

    Out-license or sell programs to pharma for late-stage clinical development and commercialization.

  • check_circle
    Patent coverage expansion

    Additional international IP milestones continue to reinforce platform defensibility.

Two lead programs, each with a different approach to the same problem.

One attacks existing tumors with engineered immune cells. The other trains the immune system to prevent cancer from forming. Both are in the clinic.

biotech Lira-cel Ovarian cancer CAR-T program

FSHR-targeted CAR-T designed for solid tumors

Lira-cel uses follicle-stimulating hormone receptor targeting, a differentiated approach to extending CAR-T into solid tumors with intraperitoneal delivery.

  • Differentiated biology: Natural ligand-based targeting strategy focused on FSHR.
  • Localized delivery: Intraperitoneal administration is designed to improve tumor access while limiting systemic exposure.
  • Visible next steps: Higher-dose cohorts, additional updates, and protocol expansion provide a clearer near-term milestone path.
vaccines Breast Cancer Vaccine

Alpha-lactalbumin vaccine advancing toward Phase 2

Targets a retired protein associated with lactation that reappears in certain cancers. Offers both therapeutic and cancer prevention potential.

  • Combination profile: Vaccine plus Keytruda showed no added adverse side effects.
  • Broader platform: Same approach is expected to apply to ovarian, lung, colon, and prostate cancers.
  • Phase 2 positioning: A neo-adjuvant design may enable faster efficacy evaluation and earlier strategic partnering discussions.

Clinical progress across both programs.

biotech Ovarian cancer CAR-T program

Lira-cel active in Phase 1

FSHR-targeted CAR-T with intraperitoneal delivery, designed to extend CAR-T activity into solid tumors.

  • 13 patients treated across four dose levels
  • Encouraging survival observations reported
  • Amended protocol enabling higher-dose evaluation
  • Periodic data updates as cohorts advance
vaccines Breast Cancer Vaccine

Phase 1 completed, advancing toward Phase 2

Alpha-lactalbumin vaccine with both therapeutic and prevention-oriented applications.

  • 35 patients dosed across three cohorts
  • Favorable tolerability and protocol-defined immune responses
  • Vaccine plus Keytruda showed no added adverse side effects
  • Neo-adjuvant Phase 2 design may enable faster efficacy evaluation

Built on a collaborative development model with leading institutions.

The operating structure is built around partnerships with leading research and clinical institutions. This supports scientific depth, clinical execution, and capital efficiency while allowing the company to advance multiple programs at the same time.

Moffitt Cancer Center, The Wistar Institute, Cleveland Clinic, Department of Defense, National Cancer Institute

Targeting massive and underserved markets.

monitoring

Breast cancer: $38B → $90B

The breast cancer market was estimated at $38.35 billion in 2023 and projected to reach $89.67 billion by 2030, with both therapeutic and prevention pathways under evaluation.

emergency

Ovarian cancer: high unmet need

Ovarian cancer remains a setting with limited effective therapies, particularly for recurrent disease where CAR-T has the potential to change outcomes.

lan

Vaccine pipeline extension

Beyond the lead programs, the preclinical vaccine pipeline extends into ovarian, lung, colon, and prostate cancers using the same retired-protein approach.

Featured presentations and coverage.

slideshow

2026 annual meeting corporate update

Ovarian cancer CAR-T program survival observations, dose escalation progress, and final Phase 1 breast cancer vaccine data.

mic

Water Tower Research podcast

Independent research coverage of recent pipeline developments and program direction.

videocam

Recent video coverage

Fox News and other media coverage of the breast cancer vaccine program and company milestones.

Latest press releases and company news.

All press releases
Anixa Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results
Ovarian Cancer CAR-T Clinical Trial Presented at Society of Gynecologic Oncology Annual Meeting
Featured on Water Tower Research Healthcare Happenings Podcast
Korean Patent Allowance for Breast Cancer Vaccine Technology
Encouraging Patient Survival Observations and Major Dose-Escalation Approval

Want to follow Anixa's clinical progress?

Get trial updates, SEC filings, and milestone announcements delivered to your inbox.

description SEC Filings